T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

T cell exhaustion and senescence for ovarian cancer immunotherapy

Zhao, J., Wang, Z., Tian, Y., Ning, J., & Ye, H. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.07.001 · Cited by 26

Immunoadjuvant therapy in the regulation of cell death in sepsis: recent advances and future directions

Islam, M. M., Watanabe, E., Salma, U., Ozaki, M., Irahara, T., Tanabe, S., Katsuki, R., Oishi, D., & Takeyama, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1493214 · Cited by 30

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy

Hu, Q., Shi, Y., Wang, H., Li, B., & Xu, Z. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00627-6 · Cited by 27

Mathematical modeling identifies Lck as a potential mediator for PD-1 induced inhibition of early TCR signaling

Arulraj, T., & Barik, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206232 · Cited by 25

Tipping the balance: inhibitory checkpoints in intestinal homeostasis

Joosse, M. E., Nederlof, I., Walker, L. S. K., & Samsom, J. N. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0113-5 · Cited by 24

Immune Modulation in Lung Cancer: Current Concepts and Future Strategies

Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 24

Resistance mechanisms to checkpoint inhibitors

Weiss, S. A., & Sznol, M. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.001 · Cited by 24

Insulin-mediated immune dysfunction in the development of preeclampsia

van Niekerk, G., Christowitz, C., & Engelbrecht, A. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02068-0 · Cited by 24

Shocking HIV-1 with immunomodulatory latency reversing agents

Kula, A., Rodari, A., Darcis, G., & Lint, C. M. V. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101478 · Cited by 28

Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth

Wang, Y., Salvucci, O., Ohnuki, H., Tran, A. D., Ha, T., Feng, J., DiPrima, M., Kwak, H., Wang, D., Yu, Y., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114089 · Cited by 23

GARP Correlates With Tumor-Infiltrating T-Cells and Predicts the Outcome of Gastric Cancer

Jiang, S., Zhang, Y., Zhang, X., Lu, B., Sun, P., Wu, Q., Ding, X., & Huang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660397 · Cited by 25

Motif-dependent immune co-receptor interactome profiling by photoaffinity chemical proteomics

Chen, X., Ji, S., Liu, Z., Yuan, X. N., Xu, C., Qi, R., He, A., Zhao, H., Song, H., Xiao, C., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.01.005 · Cited by 24

Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis

Rafael, T. S., Rotman, J., Brouwer, O. R., van der Poel, H. G., Mom, C. H., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11041101 · Cited by 27

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis

Liu, M., Cheng, X., Ni, R., Zheng, B., Huang, S., & Yang, J. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006860 · Cited by 25

A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer

Khadela, A. D., Postwala, H. I., Rana, D. K., Dave, H., Ranch, K. M., & Boddu, S. H. S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02005-w · Cited by 24

Deciphering tumor-infiltrating dendritic cells in the single-cell era

Huang, Q., Wang, F., Di, H., Li, X., Li, X., Lei, T., Yue, J., & Liu, C. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00459-2 · Cited by 27

Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy

Morel, D., Robert, C., Nikos Paragios, A., Grégoire, V., & Deutsch, É. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3632 · Cited by 29

Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules

Guo, Z., Duan, Y., Sun, K., Zheng, T., Liu, J., Xu, S., & Xu, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116579 · Cited by 26

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients

Halik, A., Tilgner, M., Silva, P., Estrada, N., Altwasser, R., Jahn, E., Heuser, M., Hou, H., Pratcorona, M., Hills, R. K., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01590-1 · Cited by 25

Tumor Necrosis Factor Receptor Superfamily in T Cell Priming and Effector Function

Muller, J., Baeyens, A., & Dustin, M. L. (2018) · Advances in immunology · doi:10.1016/bs.ai.2018.08.001 · Cited by 24

Identification of the immune checkpoint signature of multiple myeloma using mass cytometry‐based single‐cell analysis

Wang, J., Zheng, Y., Tu, C., Zhang, H., Vanderkerken, K., Menu, E., & Liu, J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1132 · Cited by 26

PD-1-stimulated T cell subsets are transcriptionally and functionally distinct

Lerrer, S., Tocheva, A. S., Bukhari, S., Adam, K., & Mor, A. (2021) · iScience · doi:10.1016/j.isci.2021.103020 · Cited by 19

Immune checkpoint blockade in hematological malignancies: current state and future potential

Pophali, P. A., Varela, J. C., & Rosenblatt, J. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1323914 · Cited by 26

Molecular insight into T cell exhaustion in hepatocellular carcinoma

Zhu, Y., Tan, H., Wang, J., Zhuang, H., Zhao, H., & Lu, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107161 · Cited by 28

SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer

Yin, J., Yang, L., Liu, Y., Shi, Q., Shi, M., Zhu, Z., Fu, D., Wang, Z., & Li, C. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010162 · Cited by 23

PD-1 receptor deficiency enhances CD30+ Treg cell function in melanoma

Lim, J. X., McTaggart, T., Jung, S. K., Smith, K. J., Hulme, G., Laba, S., Ng, Y. Q., Williams, A., Hussain, R., Coxhead, J., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02172-0 · Cited by 29

The Dendritic Cell Strikes Back

Moussion, C., & Mellman, I. (2018) · Immunity · doi:10.1016/j.immuni.2018.12.007 · Cited by 22

Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors

Ogawa, S., & Abe, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_4 · Cited by 22

Exosome and Secretion: Action On?

Hu, Y., Zhang, R., & Chen, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_19 · Cited by 25

Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab

Hutchins, B., Starling, G. C., McCoy, M. A., Herzyk, D. J., Poulet, F. M., Dulos, J., Liming, L., Kang, S. P., Fayadat‐Dilman, L., Hsieh, M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0774 · Cited by 24

SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function

Strazza, M., Adam, K. R., Lerrer, S., Straube, J., Sandigursky, S., Ueberheide, B. M., & Mor, A. (2021) · Inflammation · doi:10.1007/s10753-021-01437-8 · Cited by 23

Camrelizumab: an investigational agent for hepatocellular carcinoma

Xu, B., & Sun, H. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2022121 · Cited by 23

Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects

Banday, A. H., & Abdalla, M. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220819115849 · Cited by 25

PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?

Zwergel, C., Fioravanti, R., & Mai, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103435 · Cited by 24

Phase separation drives the formation of biomolecular condensates in the immune system

Wen, Y., & Ma, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986589 · Cited by 24

AP-1–independent NFAT signaling maintains follicular T cell function in infection and autoimmunity

Seth, A., Yokokura, Y., Choi, J.-Y., Shyer, J. A., Vidyarthi, A., & Craft, J. E. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20211110 · Cited by 23

Mechanisms and markers of malignant transformation of oral submucous fibrosis

Fen, L., Xiao, T., Wang, B., Wang, L., Liu, G., Wang, R., Xie, C., & Tang, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23314 · Cited by 23

Blockade of V‐domain immunoglobulin suppressor of T‐cell activation reprograms tumour‐associated macrophages and improves efficacy of PD‐1 inhibitor in gastric cancer

Cao, Y., Yu, K., Zhang, Z., Gu, Y., Gu, Y., Li, W., Zhang, W., Shen, Z., Xu, J., & Qin, J. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1578 · Cited by 22

Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway

Tone, M., Iwahori, K., Hirata, M., Ueyama, A., Tani, A., Haruta, J.-I., Takeda, Y., Shintani, Y., Kumanogoh, A., & Wada, H. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008334 · Cited by 26

Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity

Tooley, K., Jerby‐Arnon, L., Escobar, G., Krovi, S. H., Mangani, D., Dandekar, G., Cheng, H., Madi, A., Goldschmidt, E., Lambden, C., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101640 · Cited by 29

p110δ PI3K as a therapeutic target of solid tumours

Xenou, L., & Papakonstanti, E. A. (2020) · Clinical Science · doi:10.1042/cs20190772 · Cited by 23

Cbl-b deficiency prevents functional but not phenotypic T cell anergy

Nguyen, T. T. T., Wang, Z., Shen, L., Schroeder, A., Eckalbar, W. L., & Weiss, A. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202477 · Cited by 23

Liquid–liquid phase separation in diseases

Zhang, X., Lin, Y., Zhang, W., Zhang, Y., Wu, Q. J., Li, C., Wu, M., & Huang, Y. (2024) · MedComm · doi:10.1002/mco2.640 · Cited by 24

Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review

Jensen, G. L., Wang, X., Kuempel, J., Palaskas, N. L., Chen, Z., Yu, W., Chen, Y., Mohammad, H., Luo, W., & Chang, J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00687.2024 · Cited by 24

Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs

Guo, S., & Xi, X. (2025) · Biomarker Research · doi:10.1186/s40364-025-00755-5 · Cited by 22

CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting

Upadhyay, S., Kaur, B., & Gabr, M. T. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130310 · Cited by 19

T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia

Jing, W., Gershan, J. A., Holzhauer, S., Weber, J. J., Palen, K. A., McOlash, L., Pulakanti, K., Wesley, E., Rao, S., Johnson, B. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1309 · Cited by 22

Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors

Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22

Functional and metabolic dichotomy of murine γδ T cell subsets in cancer immunity

Lopes, N., & Silva‐Santos, B. (2020) · European Journal of Immunology · doi:10.1002/eji.201948402 · Cited by 22

Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer

Liu, J., Wang, X., Deng, Y., Yu, X., Wang, H., & Li, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766248 · Cited by 23

Protein-PAINT: Superresolution microscopy with signaling proteins

Farrell, M. V., Nunez, A. C., Yang, Z., Pérez-Ferreros, P., Gaus, K., & Goyette, J. (2022) · Science Signaling · doi:10.1126/scisignal.abg9782 · Cited by 21

CD28 and chemokine receptors: Signalling amplifiers at the immunological synapse

Molon, B., Liboni, C., & Viola, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938004 · Cited by 22

REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment

Ghorani, E., Quartagno, M., Blackhall, F. H., Gilbert, D. C., O'Brien, M. E. R., Ottensmeier, C. H. H., Pizzo, E., Spicer, J. F., Williams, A., Badman, P. D., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00095-5 · Cited by 22

Preparation and Bioevaluation of 18F-Labeled Small-Molecular Radiotracers via Sulfur(VI) Fluoride Exchange Chemistry for Imaging of Programmed Cell Death Protein Ligand 1 Expression in Tumors

Hu, X., Lv, G., Hua, D., Zhang, N., Liu, Q., Qin, S., Zhang, L., Xi, H., Qiu, L., & Lin, J. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00355 · Cited by 22

Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy

Wang, X., Lu, L., Hong, X., Wu, L., Yang, C., Wang, Y., Li, W., Yang, Y., Cao, D., Di, W. J., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113712 · Cited by 22

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma

Liu, W. R., & Shipp, M. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.310 · Cited by 23

Live Cell Microscopy: A Physical Chemistry Approach

Nandi, S., Ghosh, S., & Bhattacharyya, K. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b11689 · Cited by 22

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model

Liu, H., Weber, A. M., Morse, J. M., Kodumudi, K. N., Scott, E. N., Mullinax, J. E., Sarnaik, A. A., & Pilon‐Thomas, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196033 · Cited by 22

Inducible IFN-γ Expression for MHC-I Upregulation in Devil Facial Tumor Cells

Ong, C. E. B., Lyons, A. B., Woods, G. M., & Flies, A. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03117 · Cited by 22

Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART

Bui, J. K., Cyktor, J. C., Fyne, E., Campellone, S. C., Mason, S. W., & Mellors, J. W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211112 · Cited by 22

Site specific target binding controls RNA cleavage efficiency by the Kaposi's sarcoma-associated herpesvirus endonuclease SOX

Mendez, A. S., Vogt, C., Bohne, J., & Glaunsinger, B. A. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky932 · Cited by 18

PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies

Ding, L., Dong, H., Zhou, T. R., Wang, Y. H., Yan, T., Li, J. C., Wang, Z. Y., Liang, C., & Liang, C. (2021) · Cancer Medicine · doi:10.1002/cam4.4190 · Cited by 21

H3K4me3 mediates the NF-κB p50 homodimer binding to thepdcd1promoter to activate PD-1 transcription in T cells

Redd, P. S., Lu, C., Klement, J. D., Ibrahim, M. L., Zhou, G., Kumai, T., Celis, E., & Liu, K. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1483302 · Cited by 21

Dendritic Cell-Targeted Nanoparticles Enhance T Cell Activation and Antitumor Immune Responses by Boosting Antigen Presentation and Blocking PD-L1 Pathways

Srivastava, P., Rütter, M., Antoniraj, G. M., Ventura, Y., & David, A. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c12821 · Cited by 22

PD-1 endocytosis unleashes the cytolytic potential of checkpoint blockade in tumor immunity

Saad, E. B., Oroya, A., Anto, N. P., Bachais, M., & Rudd, C. E. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114907 · Cited by 20

CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth

Li, J., Wang, Z., Qin, X., Zhong, M., Tang, Z.-H., Qian, J., Dou, J., Hussell, T., King, P. D., Nunès, J. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60456-3 · Cited by 22

Characterization of B cell‐mediated PD‐1/PD‐L1 interaction in pancreatic cancer patients

Tong, D., Guan, J., Sun, J., Zhao, C., Chen, S., Zhang, Z., & Zhou, Z. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13317 · Cited by 22

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance

Huang, Q., Lei, Y., Li, X., Guo, F., & Liu, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580140 · Cited by 22

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

Hurkmans, D. P., Verdegaal, E. M. E., Hogan, S. A., de Wijn, R., Hovestad, L., van den Heuvel, D. M. A., Ruijtenbeek, R., Welters, M. J. P., van Brakel, M., Basak, E. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001607 · Cited by 20

Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells

Strazza, M., Azoulay‐Alfaguter, I., Peled, M., Adam, K. R., & Mor, A. (2021) · Communications Biology · doi:10.1038/s42003-021-02225-8 · Cited by 21

Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis

Tang, X., Shi, A., Xiong, Y., Zheng, K., Liu, Y., Shi, X.-G., Jiang, T., & Zhao, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693321 · Cited by 22

Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1

Ramaswamy, M., Kim, T. I., Jones, D. C., Ghadially, H., Mahmoud, T. I., Garcia, A., Browne, G. J., Ζήνωνος, Ζ., Puplampu-Dove, Y., Riggs, J. M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0218 · Cited by 21

Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling

Geng, C., Chen, J., Song, T., Jung, J. H., Long, M., Song, M., Ji, T., Min, B. S., Lee, J. G., Peng, B., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.05.012 · Cited by 23

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer

Wang, L., Yang, Z., Guo, F., Chen, Y., Wei, J., Dai, X., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1227797 · Cited by 22

Using CombiCells, a platform for titration and combinatorial display of cell surface ligands, to study T-cell antigen sensitivity modulation by accessory receptors

Patel, A., André, V., Eguiguren, S. B., Barton, M. I., Burton, J., Denham, E. M., Pettmann, J., Mørch, A. M., Kutuzov, M. A., Siller‐Farfán, J. A., et al. (2023) · The EMBO Journal · doi:10.1038/s44318-023-00012-1 · Cited by 20

According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1 low HCV-Specific CD8 + Cell Reactivity

Cubero, E. M., Subirá, D., Sanz‐de‐Villalobos, E., Parra-Cid, T., Madejón, A., Miquel, J., Olveira, A., Praetorius, A. G., García‐Samaniego, J., & Larrubia, J. R. (2017) · Journal of Virology · doi:10.1128/jvi.01443-17 · Cited by 21

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody

Gombos, R. B., Gonzalez, A., Manrique, M. L., Chand, D. S., Savitsky, D. A., Morin, B. M., Breous-Nystrom, E., Dupont, C. D., Ward, R., Mundt, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191926 · Cited by 21

PD-1 suppresses the maintenance of cell couples between cytotoxic T cells and target tumor cells within the tumor

Ambler, R., Edmunds, G. L., Tan, S. L., Cirillo, S., Pernes, J. I., Ruan, X., Huete‐Carrasco, J., Wong, C. C. W., Lu, J., Ward, J., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aau4518 · Cited by 23

BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways

Yue, P., Harper, T. A., Bacot, S. M., Chowdhury, M., Lee, S., Akue, A. D., KuKuruga, M. A., Wang, T., & Feldman, G. M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512456 · Cited by 20

Opportunities and challenges for the development of covalent chemical immunomodulators

Backus, K. M., Cao, J. X., & Maddox, S. M. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.050 · Cited by 21

Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications

Krueger, J., Rudd, C. E., & Taylor, A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101295 · Cited by 22

SHP2 allosteric inhibitor TK-453 alleviates psoriasis-like skin inflammation in mice via inhibition of IL-23/Th17 axis

Wang, M., Li, T., Ouyang, Z., Tang, K., Zhu, Y., Song, C., Sun, H., Yu, B., Ji, X., & Sun, Y. (2022) · iScience · doi:10.1016/j.isci.2022.104009 · Cited by 20

Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells

Zhang, F., Ding, X., Huang, H., Jiang, H., Jiang, J., & Zheng, X. W. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0105 · Cited by 25

Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study

Gao, Y. J., Qi, F., Zhou, W., Jiang, P., Hu, M., Wang, Y., Song, C., Han, Y., Li, D., Qin, N., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00291-6 · Cited by 20

HIV-1 Tat – TLR4/MD2 interaction drives the expression of IDO-1 in monocytes derived dendritic cells through NF-κB dependent pathway

Bahraoui, E., Serrero, M. C., & Planès, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-64847-y · Cited by 21

PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment

Le, C. T., Khuat, L. T., Caryotakis, S. E., Wang, M., Dunai, C., Nguyen, A. V., Vick, L. V., Stoffel, K. M., Blazar, B. R., Monjazeb, A. M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590568 · Cited by 19

Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma

Sheng, Q., Tian, W., Dou, X., Zhang, C., Li, Y., Han, C. Q., Fan, Y., Lai, P., & Ding, Y. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i11.1255 · Cited by 20

Determination of the molecular reach of the protein tyrosine phosphatase SHP-1

Clemens, L., Kutuzov, M. A., Bayer, K. V., Goyette, J., Allard, J. F., & Dushek, O. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.03.019 · Cited by 18

Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses

Bu, X., Juneja, V. R., Reynolds, C. G., Mahoney, K. M., Bu, M. T., McGuire, K. A., Maleri, S., Hua, P., Zhu, B., Klein, S. R., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0493 · Cited by 20

New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases

Jin, D., Jiang, Y., Lu, C., Wei, J., & Sun, J. M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108935 · Cited by 20

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion

Taylor, J. G., Truelove, E., Clear, A. J., Calaminici, M., & Gribben, J. G. (2022) · Haematologica · doi:10.3324/haematol.2022.280014 · Cited by 20

Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research

Chakraborty, R., Darido, C., Liu, F., Maselko, M., & Ranganathan, S. (2023) · Cancers · doi:10.3390/cancers15030852 · Cited by 20

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma

Luca, F. D., Allegra, A., Chio, C. D., Previti, S., Zappalà, M., & Ettari, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043136 · Cited by 21

The metabolic cross-talk between cancer and T cells

Miguel, S. C.-D., Lucianer, G., & Elia, I. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.03.004 · Cited by 22

Targeting PI3Kα increases the efficacy of anti‐PD ‐1 antibody in cervical cancer

Jiang, W., Ouyang, X., Li, C., Long, Y., Chen, W., Ji, Z., Shen, X., Xiang, L., & Yang, H. (2023) · Immunology · doi:10.1111/imm.13682 · Cited by 19

TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways

Chan, W., Cao, Y. M., Zhao, X., Schrom, E. C., Jia, D., Song, J., Sibener, L. V., Dong, S., Fernandes, R. A., Bradfield, C. J., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20231242 · Cited by 21

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

Chocarro, L., Blanco, E., Fernández, L., Garnica, M., Zuazo, M., Garcia, M. J., Bocanegra, A., Echaide, M., Johnston, C. M., Edwards, C., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00098-y · Cited by 21

A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies

Moore, G. L., Zeng, V. G., Diaz, J. E., Bonzon, C., Avery, K. N., Rashid, R., Qi, J., Nam, D. H., Jacinto, J. M., Dragovich, M. A., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0327 · Cited by 20

Role of TRAFs in Signaling Pathways Controlling T Follicular Helper Cell Differentiation and T Cell-Dependent Antibody Responses

Pedros, C., Altman, A., & Kong, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02412 · Cited by 21

Immunological and clinical implications of immune checkpoint blockade in human cancer

Kim, H., & Park, S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01140-1 · Cited by 20

PD-1 targets CD28

Dempsey, L. A. (2017) · Nature Immunology · doi:10.1038/ni.3739 · Cited by 3

PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation

Mizuno, R., Sugiura, D., Shimizu, K., Maruhashi, T., Watada, M., Okazaki, I., & Okazaki, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00630 · Cited by 186

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161

PD-1 Blockade–Mediated Rescue of Exhausted T Cells Requires CD28

(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2017-055 · Cited by 1

PD1 functions by inhibiting CD28‐mediated co‐stimulation

O’Donnell, J. S., Smyth, M. J., & Teng, M. W. L. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.15 · Cited by 10